title: Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.
abstract: The taxanes are a class of chemotherapeutic agents that are widely used in the treatment of various solid tumors. Although taxanes are highly effective in cancer treatment, their use is associated with serious complications attributable to large interindividual variability in pharmacokinetics and a narrow therapeutic window. Unpredictable toxicity occurrence necessitates close patient monitoring while on therapy and adverse effects frequently require decreasing, delaying or even discontinuing taxane treatment. Currently, taxane dosing is based primarily on body surface area, ignoring other factors that are known to dictate variability in pharmacokinetics or outcome. This article discusses three potential strategies for individualizing taxane treatment based on patient information that can be collected before or during care. The clinical implementation of pharmacogenetics, enzyme probes or therapeutic drug monitoring could enable clinicians to personalize taxane treatment to enhance efficacy and/or limit toxicity.
authors.affiliation: UNC Institute for Pharmacogenomics & Individualized Therapy, University of North Carolina at Chapel Hill, 120 Mason Farm Road, CB 7361, Chapel Hill, NC 27599, USA.
authors.forename: Stefanie D
authors.initials: SD
authors.lastname: Krens
authors.forename: Howard L
authors.initials: HL
authors.lastname: McLeod
authors.forename: Daniel L
authors.initials: DL
authors.lastname: Hertz
mesh_terms: D000970:Antineoplastic Agents / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics*; D001952:Bridged-Ring Compounds / Q000378:metabolism* / Q000493:pharmacokinetics / Q000627:therapeutic use; D000077143:Docetaxel; D016903:Drug Monitoring; D005260:Female; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics; D017239:Paclitaxel / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use; D010597:Pharmacogenetics; D057285:Precision Medicine; D043823:Taxoids / Q000378:metabolism* / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001952:Bridged-Ring Compounds; D043823:Taxoids; D000077143:Docetaxel; C080625:taxane; D017239:Paclitaxel
references.citation: J Clin Oncol. 1995 Jan;13(1):180-90
references.pmid: 7799018
references.citation: Clin Pharmacol Ther. 2008 Jul;84(1):111-8
references.pmid: 18183036
references.citation: Breast Cancer Res Treat. 2011 Dec;130(3):993-1002
references.pmid: 21766209
references.citation: Lancet Oncol. 2004 Mar;5(3):158-64
references.pmid: 15003198
references.citation: Pharmacogenet Genomics. 2009 Dec;19(12):979-83
references.pmid: 21151855
references.citation: Biochim Biophys Acta. 2009 May;1794(5):860-71
references.pmid: 19285158
references.citation: J Clin Oncol. 1999 Jun;17(6):1786-93
references.pmid: 10561216
references.citation: Basic Clin Pharmacol Toxicol. 2012 Feb;110(2):199-204
references.pmid: 21955855
references.citation: Eur J Cancer. 2005 Jul;41(10):1460-6
references.pmid: 15913989
references.citation: Ann Oncol. 2009 Feb;20(2):272-7
references.pmid: 18836089
references.citation: Oncol Rep. 2010 Jan;23(1):271-8
references.pmid: 19956892
references.citation: Br J Clin Pharmacol. 2006 Jul;62(1):56-70
references.pmid: 16842379
references.citation: BJU Int. 2007 May;99(5):1047-55
references.pmid: 17437439
references.citation: Nat Rev Drug Discov. 2004 Sep;3(9):739-48
references.pmid: 15340384
references.citation: Clin Pharmacol Ther. 2006 Jun;79(6):570-80
references.pmid: 16765145
references.citation: Lung Cancer. 2005 Aug;49(2):245-51
references.pmid: 16022919
references.citation: J Clin Oncol. 2009 Jul 20;27(21):3540-6
references.pmid: 19470925
references.citation: Cancer Chemother Pharmacol. 2011 Nov;68(5):1255-62
references.pmid: 21437702
references.citation: Pharmacogenetics. 2003 Aug;13(8):481-94
references.pmid: 12893986
references.citation: Drug Metab Rev. 2007;39(4):699-721
references.pmid: 18058330
references.citation: Cancer Chemother Pharmacol. 2011 Dec;68(6):1565-73
references.pmid: 21547572
references.citation: Clin Cancer Res. 2000 Apr;6(4):1255-8
references.pmid: 10778948
references.citation: Ann Oncol. 2013 Jun;24(6):1472-8
references.pmid: 23413280
references.citation: Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):854-9
references.pmid: 16467099
references.citation: Clin Cancer Res. 2004 Dec 15;10(24):8325-31
references.pmid: 15623609
references.citation: Cancer Sci. 2008 May;99(5):967-72
references.pmid: 18294295
references.citation: Cancer Chemother Pharmacol. 2012 Jan;69(1):125-35
references.pmid: 21626050
references.citation: Science. 2007 Jan 26;315(5811):525-8
references.pmid: 17185560
references.citation: Clin Cancer Res. 2012 Sep 15;18(18):5099-109
references.pmid: 22843789
references.citation: Oncologist. 2012;17(5):620-30
references.pmid: 22531359
references.citation: Curr Drug Metab. 2006 Jan;7(1):23-37
references.pmid: 16454691
references.citation: J Clin Pharmacol. 2005 Jun;45(6):674-82
references.pmid: 15901749
references.citation: Clin Cancer Res. 2004 Apr 1;10(7):2237-44
references.pmid: 15073098
references.citation: J Clin Oncol. 2009 Mar 10;27(8):1168-76
references.pmid: 19204205
references.citation: Basic Clin Pharmacol Toxicol. 2009 Feb;104(2):130-7
references.pmid: 19143748
references.citation: Cancer Invest. 1995;13(4):381-404
references.pmid: 7627725
references.citation: Clin Pharmacokinet. 2006;45(3):235-52
references.pmid: 16509758
references.citation: Eur J Pharmacol. 2010 Feb 10;627(1-3):92-8
references.pmid: 19903471
references.citation: Cancer Biol Ther. 2005 Aug;4(8):815-8
references.pmid: 16210916
references.citation: Mol Interv. 2004 Jun;4(3):157-62
references.pmid: 15210869
references.citation: Pharmacogenetics. 2000 Jun;10(4):343-53
references.pmid: 10862525
references.citation: Cancer Res. 1997 Jul 15;57(14):3026-31
references.pmid: 9230218
references.citation: Eur J Cancer. 2006 Nov;42(17):2893-6
references.pmid: 16950614
references.citation: Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6125-32
references.pmid: 17062689
references.citation: Invest New Drugs. 2001 May;19(2):163-9
references.pmid: 11392450
references.citation: Nat Rev Drug Discov. 2010 Sep;9(9):677-8
references.pmid: 20811375
references.citation: Clin Cancer Res. 2007 Nov 1;13(21):6410-8
references.pmid: 17975154
references.citation: Clin Cancer Res. 2003 Mar;9(3):1077-82
references.pmid: 12631610
references.citation: Int J Clin Oncol. 2007 Aug;12(4):284-90
references.pmid: 17701008
references.citation: Fundam Clin Pharmacol. 2002 Aug;16(4):253-62
references.pmid: 12570013
references.citation: Cancer Chemother Pharmacol. 2008 Aug;62(3):551-7
references.pmid: 18064462
references.citation: Cancer Res. 2000 Jul 1;60(13):3440-4
references.pmid: 10910054
references.citation: Breast Cancer Res Treat. 2011 May;127(1):153-62
references.pmid: 21350820
references.citation: Clin Cancer Res. 1995 Jun;1(6):599-606
references.pmid: 9816021
references.citation: Clin Pharmacol Ther. 2006 Dec;80(6):657-67
references.pmid: 17178266
references.citation: J Clin Oncol. 2005 Feb 20;23(6):1061-9
references.pmid: 15657405
references.citation: Drug Metab Dispos. 1990 Nov-Dec;18(6):895-901
references.pmid: 1981534
references.citation: Clin Chem. 1993 Nov;39(11 Pt 2):2419-30
references.pmid: 8222253
references.citation: J Clin Oncol. 1997 Jan;15(1):317-29
references.pmid: 8996159
references.citation: Int J Gynecol Cancer. 2009 Dec;19 Suppl 2:S30-4
references.pmid: 19955911
references.citation: Br J Cancer. 1999 Sep;81(2):330-5
references.pmid: 10496361
references.citation: J Clin Oncol. 2000 Jun;18(11):2301-8
references.pmid: 10829051
references.citation: Pharmacogenomics. 2010 May;11(5):621-3
references.pmid: 20415548
references.citation: Cancer Chemother Pharmacol. 2007 Jul;60(2):305-8
references.pmid: 17124593
references.citation: Curr Opin Oncol. 2007 Nov;19(6):586-9
references.pmid: 17906456
references.citation: Clin Pharmacol Ther. 1990 Aug;48(2):120-9
references.pmid: 2116259
references.citation: Int J Cancer. 2010 Dec 15;127(12):2959-64
references.pmid: 21351274
references.citation: Clin Cancer Res. 1999 Mar;5(3):543-9
references.pmid: 10100705
references.citation: Clin Pharmacol Ther. 1999 Sep;66(3):224-31
references.pmid: 10511057
references.citation: Clin Cancer Res. 2005 Jul 1;11(13):4843-50
references.pmid: 16000582
references.citation: Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6100-5
references.pmid: 17062686
references.citation: Clin Chim Acta. 2009 Jun 27;404(2):160-5
references.pmid: 19332043
references.citation: Pharmacogenetics. 2001 Oct;11(7):597-607
references.pmid: 11668219
references.citation: Cancer Chemother Pharmacol. 2004 Sep;54(3):265-72
references.pmid: 15133628
references.citation: Cancer Chemother Pharmacol. 2011 Jun;67(6):1353-62
references.pmid: 20798939
references.citation: Gastric Cancer. 2007;10(1):52-7
references.pmid: 17334719
references.citation: Clin Cancer Res. 2005 Nov 15;11(22):8097-104
references.pmid: 16299241
references.citation: Carcinogenesis. 1999 Aug;20(8):1607-13
references.pmid: 10426814
references.citation: Drug Metab Dispos. 2002 Nov;30(11):1149-52
references.pmid: 12386117
references.citation: Pharmacogenetics. 1998 Oct;8(5):391-401
references.pmid: 9825831
references.citation: Cancer Sci. 2006 Mar;97(3):235-41
references.pmid: 16542221
references.citation: J Natl Cancer Inst. 1992 Dec 2;84(23):1781-8
references.pmid: 1359154
references.citation: Drug Metab Dispos. 2011 Feb;39(2):247-55
references.pmid: 21056987
references.citation: Cancer Chemother Pharmacol. 2012 May;69(5):1221-7
references.pmid: 22271208
references.citation: Pharmacogenomics J. 2011 Apr;11(2):121-9
references.pmid: 20212519
references.citation: Cancer Res. 2012 Sep 15;72(18):4744-52
references.pmid: 22805305
references.citation: J Clin Oncol. 2002 Sep 1;20(17):3683-90
references.pmid: 12202670
references.citation: Respiration. 2009;78(1):49-55
references.pmid: 18812689
references.citation: Br J Haematol. 1999 Jun;105(3):696-700
references.pmid: 10354134
references.citation: J Clin Oncol. 2012 Jun 10;30(17):2055-62
references.pmid: 22547591
references.citation: Mol Cancer Ther. 2008 Jan;7(1):19-26
references.pmid: 18187806
references.citation: J Clin Oncol. 1993 Nov;11(11):2127-35
references.pmid: 7901342
references.citation: Br J Clin Pharmacol. 2004 Jan;57(1):44-53
references.pmid: 14678339
references.citation: Pharmacogenomics J. 2007 Oct;7(5):362-5
references.pmid: 17224914
references.citation: Laryngoscope. 2009 Aug;119(8):1484-90
references.pmid: 19504558
references.citation: Clin Pharmacol Ther. 2009 Feb;85(2):155-63
references.pmid: 18509327
references.citation: J Pharm Sci. 2011 Oct;100(10):4205-9
references.pmid: 21702053
references.citation: Clin Cancer Res. 2011 Jan 15;17(2):353-62
references.pmid: 21224369
references.citation: Pharmacogenomics J. 2011 Apr;11(2):113-20
references.pmid: 20368717
references.citation: Clin Cancer Res. 2008 Jul 15;14(14):4543-9
references.pmid: 18628469
references.citation: Sci Transl Med. 2011 Nov 30;3(111):111ra121
references.pmid: 22133722
references.citation: J Clin Oncol. 1998 Jan;16(1):187-96
references.pmid: 9440742
references.citation: Breast Cancer Res Treat. 2010 Nov;124(2):593-8
references.pmid: 20632082
references.citation: Breast Cancer Res Treat. 2012 Jul;134(1):401-10
references.pmid: 22527101
references.citation: Drug Metab Dispos. 1996 Jun;24(6):655-8
references.pmid: 8781781
references.citation: J Clin Oncol. 1987 Aug;5(8):1232-9
references.pmid: 2887641
references.citation: Pharmacogenomics. 2007 Jul;8(7):803-15
references.pmid: 17638515
references.citation: Gynecol Oncol. 2009 May;113(2):264-9
references.pmid: 19203783
references.citation: Anticancer Res. 2003 Jan-Feb;23(1B):681-6
references.pmid: 12680167
references.citation: Clin Cancer Res. 2011 Jan 15;17(2):294-301
references.pmid: 21097690
references.citation: BMC Cancer. 2010 Sep 27;10:511
references.pmid: 20875115
references.citation: J Clin Oncol. 2004 Apr 15;22(8):1382-8
references.pmid: 15007088
references.citation: J Clin Oncol. 2005 Jan 20;23(3):413-21
references.pmid: 15585753
references.citation: Clin Cancer Res. 2006 Oct 1;12(19):5786-93
references.pmid: 17020985
references.citation: Clin Cancer Res. 2012 Aug 15;18(16):4441-8
references.pmid: 22718863
references.citation: Br J Clin Pharmacol. 2012 Jul;74(1):197-200
references.pmid: 22680343
references.citation: Pharmacogenomics J. 2010 Jun;10(3):191-9
references.pmid: 20038957
references.citation: Clin Pharmacol Ther. 2005 Jan;77(1):43-53
references.pmid: 15637530
references.citation: Clin Pharmacol Ther. 2006 Sep;80(3):228-34
references.pmid: 16952489
references.citation: Ann Oncol. 2009 Apr;20(4):736-40
references.pmid: 19223573
references.citation: Nat Rev Cancer. 2004 Apr;4(4):253-65
references.pmid: 15057285
references.citation: J Clin Oncol. 2006 Apr 1;24(10):1633-42
references.pmid: 16575015
references.citation: Clin Pharmacokinet. 2012 Sep 1;51(9):607-17
references.pmid: 22804749
references.citation: Clin Pharmacokinet. 2006;45(6):611-22
references.pmid: 16719542
references.citation: Clin Cancer Res. 2008 Sep 1;14(17):5594-601
references.pmid: 18765553
references.citation: Cancer Chemother Pharmacol. 2010 Feb;65(3):437-46
references.pmid: 19568750
references.citation: Int J Clin Oncol. 2003 Jun;8(3):156-61
references.pmid: 12851839
references.citation: Drug Metab Dispos. 2008 Jan;36(1):73-80
references.pmid: 17913794